North Tees and Hartlepool NHS foundation trust
Stockton-on-Tees, County Durham, TS19 8PE, United Kingdom
Location status: Recruiting
NCT Number: NCT06682936
Patients with malignant pleural disease often experience a significant symptom burden and a short life expectancy. The cornerstone of their treatment is relieving breathlessness by draining fluid from around the lungs and attempting to prevent further fluid build up. Inpatient chest drainage and talc pleurodesis remains the most successful method of stopping the fluid build up but this often requires an average hospital stay of four days. This can be an inappropriate length of time for this patient group. Our study would investigate whether this treatment could be provided on an outpatient, ambulatory basis and facilitate a greater quality of life.
The investigators would assess deliverability of the trial protocol and collect patient feedback to see if our patients consider it an acceptable and worthwhile intervention.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Stockton-on-Tees, County Durham, TS19 8PE, United Kingdom
Location status: Recruiting
Eligible patients will be offered enrolment in the trial along with standard of care options.
Participants who agree to take part in the trial would be consented for chest drain, talc pleurodesis on an ambulatory pathway.
On day 1 a standard chest drain would be inserted in the morning and large volume fluid removal would commence using an underwater seal bottle- as per standard care. A chest x-ray would be undertaken to confirm drain position, as per standard care. The investigators would remove 1000mls of fluid (stopping earlier if not tolerated) and the clamp the drain for one hour. The investigators would then open the drain again and drain up to 500mls before again clamping for one hour. The investigators would repeat this process as frequently as possible until the end of the working day. The drain would then be connected to an ambulatory bag instead of the underwater seal bottle and left in the open position. The patient would then be sent home to return on day 2.
On day 2 the drain would be flushed, aspirated and the output assessed. If there is still fluid output the investigators would drain up to 500mls and close the drain for an hour and repeat. If there is no further output the investigators would undertake a chest x ray to ensure the effusion has resolved and the lung has fully inflated. If it has the investigators would proceed to talc slurry instillation (with 20mls 1% lidocaine as per standard practice) and clamp the drain for 2 hours. After this the investigators would open the drain again and drain up to 500mls and close the drain for an hour. The investigators would repeat this as required and again the patient would return home with an ambulatory bag left open.
If the effusion has resolved but the lung has not fully expanded due to underlying disease then the investigators would simply remove the chest drain as pleurodesis will not be possible.
On day 3 the drain would be flushed, aspirated and the output assessed. If there is still fluid output the investigators would drain up to 500mls and close the drain for an hour and repeat. If there is no further output the investigators would undertake a chest x ray to ensure the effusion has resolved and the lung has fully inflated. the investigators would then remove the drain and repeat the x-ray to confirm there have been no complications. the investigators would then consider the intervention complete and revert to standard care (open access follow up )
If there was still significant fluid output the investigators would repeatedly drain 500ml volumes of fluid and clamp the drain for an hour after each 500ml until dry.
The investigators would ask patients to complete a very brief questionnaire (visual analogue scale) on breathlessness and chest pain on day 1 - before intervention, 1 hour post drain insertion, at the end of the day and on day 2 and 3 on first encounter and at the end of the day. The investigators would also repeat the questionnaire on day 30 along with their satisfaction with the procedure and if participants would have preferred to have stayed in hospital for the procedure (and why)
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
a chest drain will be inserted, fluid drained and medical talc instilled on an ambulatory basis
Time frame: 5 days
Can the investigators successfully deliver the described ambulatory pleruodesis protocol within the 5 day time frame and what is the success rate of the protocol delivery.
Time frame: 5 days
Questionnaire on breathlessness and chest pain at day 5 and semi-structured interview on the patient experience of the intervention
Time frame: 30 days
Questionnaire on breathlessness and chest pain at day 30 and semi-structured interview of the patient experience of the intervention
Contact information is provided by the study sponsor or research team.
David Rollins
Other
Can Talc Pleurodesis for Malignant Pleural Effusion be Performed on an Ambulatory Basis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05620329
Breast Cancer, Breast Diseases
Chapel Hill, North Carolina, United States
View Trial DetailsNCT04322136
Cancer, Malignant Pleural Effusion
Nedlands, Western Australia, Australia
View Trial DetailsNCT00896285
Malignant Pleural Effusion, Neoplasms
Sacramento, California, United States
View Trial DetailsNCT04806412
Bronchial Neoplasms, Carcinoma, Bronchogenic
Næstved, Region Sjælland, Denmark
View Trial Details